Root Financial Partners 13F: Adds $1.3M to AbbVie (ABBV) Stake
Key Points
- Root Financial Partners expanded its stake in AbbVie Inc. by 5,115 shares to finish the period with 12,318 shares valued at $3,222,336.
- AbbVie shares recently traded around $284.80, sitting above their 50-day and 200-day moving averages.
- The drug maker is scheduled to release its next earnings report on October 30, 2026.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Root Financial Partners boosted its position in AbbVie Inc. (NYSE:ABBV) by 71.0% during the period, according to a Form 13F filing with the Securities and Exchange Commission on October 21, 2026. AbbVie shares closed at $284.80 on the day of the filing.
ABBV
AbbVie Inc.
What Changed in Root Financial Partners's AbbVie Position
Root Financial Partners added 5,115 shares to its portfolio during the timeframe. The fund held 7,203 shares previously and wrapped up the period with 12,318 shares. The total reported value of the stake reached $3,222,336.
Other Institutional Activity in AbbVie
Other institutional investors adjusted their holdings around the same time. Intech Investment Management reduced its stake by 18,393 shares, ending with 49,673 shares worth about $12,547,151. Pictet North America Advisors opened a new position by purchasing 2,747 shares valued at about $718,588. Sumitomo Mitsui DS Asset Management Company lowered its holdings by 32,919 shares to finish with 291,632 shares valued at $76,288,015. AlphaStar Capital Management grew its stake by 2,299 shares, ending with 19,380 shares worth about $5,069,641. Y-Intercept sold out entirely, shedding 74,248 shares to leave its holdings at zero.
AbbVie Inc. Stock Down 0.2%
AbbVie shares recently traded around $284.80 as of October 22, 2026, matching their event close. The stock trades above its 50-day moving average of $262.45 and well above its 200-day moving average of $233.95. The recent price sits 2.3% below its 52-week high of $291.40 and 49.3% above its 52-week low of $190.75.
Recent Earnings
AbbVie posted trailing-twelve-month revenue of $64,385,998,848 alongside a net margin of 9.8%. The next quarterly earnings update is scheduled for October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie pays an annual dividend rate of $6.92 per share.
Insider Buying and Selling at AbbVie Inc.
Company insiders completed several transactions earlier in the year, including General Counsel Perry C. Siatis and other officers.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock leading up to the filing, with firms like JP Morgan and Barclays adjusting targets.
About AbbVie
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, and sells medicines and therapies globally. Its treatments target immunology conditions, blood cancers, and lung cancer. Institutional filings like this one offer a window into how professional managers position their portfolios in major pharmaceutical names.
Bottom Line
Investors will look to AbbVie's upcoming earnings report on October 30, 2026, for fresh financial details. Additional institutional filings will continue to show how portfolio managers adjust their stakes in the drug maker.
Related Filing Alerts
Source: Root Financial Partners's 13F filing on $ABBV (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts